Abstract:Background: In 1988, the Systolic Hypertension in China (Syst-China) Collaborative Group initiated the placebo-controlled Syst-China trial to investigate whether antihypertensive drug treatment could reduce the incidence of fatal and nonfatal stroke in older Chinese patients with isolated systolic hypertension.Objectives: To explore (1) whether the benefits of active treatment were evenly distributed across 4 strata, prospectively defined according to sex and previous cardiovascular complications, and (2) whether the morbidity and mortality results were influenced by age, level of systolic or diastolic blood pressure (BP), smoking or drinking habits, or diabetes mellitus at enrollment.Methods: Eligible patients had to be 60 years or older with a sitting systolic BP of 160 to 219 mm Hg and diastolic BP less than 95 mm Hg. After stratification for center, sex, and previous cardiovascular complications, 1253 patients were assigned to active treatment starting with nitrendipine (10-40 mg/d), with the possible addition of captopril (12.5-50.0 mg/d), and/or hydrochlorothiazide (12.5-50 mg/d). In the 1141 control patients, matching placebos were used similarly.Results: Male sex, previous cardiovascular complications, older age, higher systolic BP or lower diastolic BP, living in northern China, smoking, and diabetes mellitus significantly and independently increased the risk of 1 or more of the following end points: total or cardiovascular mortality, all fatal and nonfatal cardiovascular end points, all strokes, and all cardiac end points. In the placebo-control group diabetes raised the risk of all end points 2- to 3-fold (P less than or equal to .05). However, active treatment reduced the excess risk associated with diabetes to a nonsignificant level (P values ranging from .12-.86) except for cardiovascular mortality (P = .04). Cox regression with adjustments applied for significant covariates suggested that active treatment may reduce total mortality more (P = .06) in women and stroke more (P = .07) in men and that it may provide better protection against cardiac end points in nonsmokers than smokers (P = .04). Otherwise, the benefits of active treatment were equally manifest, regardless of the enrollment characteristics of the patients, and regardless of whether active treatment consisted of only nitrendipine or of nitrendipine associated with other active drugs.Conclusions: In elderly Chinese patients with isolated systolic hypertension, stepwise antihypertensive drug treatment, starting with the dihydropyridine calcium channel blocker nitrendipine, improved prognosis. The benefit was particularly evident in diabetic patients; for cardiac end points it tended to be larger in nonsmokers. Otherwise, the benefit of active treatment was not significantly influenced by the characteristics of the patients at enrollment in the trial.

The Therapeutic Alliance of Tong-Xin-luo Capsule and Conventional Antihypertensive Therapy on Prevention of Arteriosclerosis in Elderly Male Patient with Hypertension

[Atherosclerosis and Androgen Levels in Elderly Males].

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia

The Effect of Atorvastatin on Lowering Lipids in Elderly Patients with Type 2 Diabetic Mellitus Plus Hyperlipidemia

Clinical Research of Tongxinluo Capsule in the Treatment of Senile Cerebral Arteriosclerosis

To assess the treatment outcome on lower blood pressure in the old by using candesartan cilexetil and amlodipine besylate

Clinical study on hydrochlorothiazide combined with valsartan in treatment of elderly hypertension

Uncontrolled Hypertension Increases With Age And Associates With All-Cause Mortality In An Elderly Community-Dwelling Chinese Population In Shanghai

Effects Of Combined Therapy Of Xuezhikang Capsule ((Sic)) And Valsartan On Hypertensive Left Ventricular Hypertrophy And Heart Rate Turbulence

Clinical Trial of Qianglitianmaduzhong Capsule for Geriatric Hypertension Combined with Routine Treatment

Investigation on effect of low-dosage Atorvastatin plus Asprin on carotid atherosclerosis plaque and inflammation in elderly patients

Efficacy of Xuefu Zhuyu Capsule combined with conventional Western medicine treatment for angina pectoris in coronary heart disease

Effects of Combined Therapy of Xuezhikang Capsule and Valsartan on Hypertensive Left Ventricular Hypertrophy and Heart Rate Turbulence.

Clinical observation of Antihypertensive Therapy in the Elderly Patients with Isolated Systolic Hypertension

Anti-atherosclerosis strategy for patients with hypertension: antihypertensive therapy combined with cholesterol-lowering therapy

Effect of Tongxinluo Capsule on Endothelial Function in Stable Angina Pectoris Patients

Influence of amlodipine combined with valsartan on vascular elasticity function and myocardial cells apoptosis of elderly patients with hypertension

Traditional Chinese versus integrative treatment in elderly patients with isolated systolic hypertension: a multicenter, randomized, double-blind controlled trial

Effects of tongxinluo capsule on platelet activating and inflammation factors as well as vascular endothelial function in patients with essential hypertension complicated with diabetes mellitus]

Effects of 12-Week Supplementation of a Polyherbal Formulation in Old Adults with Prehypertension/Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial

Chinese Trial on Isolated Systolic Hypertension in the Elderly